Elicio Therapeutics (ELTX) Cash & Equivalents (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Cash & Equivalents data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 18.54% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 18.54% YoY), and the FY2025 full-year result was $18.6 million, up 5.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.9 million, down from $18.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $73.0 million in Q1 2022 and bottomed at $598000.0 in Q2 2022.
• The 5-year median for Cash & Equivalents is $14.9 million (2026), against an average of $17.2 million.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 99.49%; it then soared 3525.75% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $6.2 million in 2022, then jumped by 109.45% to $12.9 million in 2023, then jumped by 36.64% to $17.6 million in 2024, then climbed by 5.36% to $18.6 million in 2025, then dropped by 19.47% to $14.9 million in 2026.
• The last three Cash & Equivalents figures came in at $14.9 million (Q1 2026), $18.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.

Peer Comparison